Since its establishment in 2021, the RWE Alliance has operated in service of four top-line priorities: (1) advancing and supporting FDA’s RWE Framework, (2) encouraging the use of RWE to better understand treatment effects in underrepresented populations; (3) enhancing opportunities for RWE organizations to consult with FDA; and (4) increasing communication on the generation and […]
